A continuum in translational research
Management of your translational neuroscience research project by NeurAtris
You want to identify a new target or biomarker to develop a pipeline of innovative therapies
1
Identification & validation of the therapeutic target and predictive biomarkers
You have already identified therapeutic candidates and you wish to select the most promising ones
2
Identification, optimisation & validation of biotherapeutic strategies
You have already selected your therapeutic candidates and you wish to validate your hypothesis on relevant animal models and characterised cohorts
3
Preclinical validation of biotherapeutic strategies (preclinical PoC)
4
Clinical validation of biotherapeutic strategies (Clinical PoC)
Diseases concerned:
NeurATRIS provides you with the human (dedicated project managers) and technical resources necessary to accompany you throughout your translational research project, according to the following scheme:
1
Definition of timetable and expected results
2
Definition of protocols and experimental designs
3
Operational management of the project
4
Client support and reporting
Quality and regulatory management
Commitments of a partner network
The structuring and monitoring of your project also allow you to facilitate the procedures related to regulations and quality.
The support offered by NeurATRIS, with its GLP and non-GLP compliant facilities, will not only accelerate the development of your projects but also reduce the regulatory timeframe and associated risks as well as ensure their quality.
The facilities dedicated to the production of biotherapeutics are GMP compliant and each clinical protocol complies with ethical laws, particularly for patient cohorts. Similarly, NeurATRIS' clinical facilities comply with French and European legislation and regulations on good clinical practices.
Several NeurATRIS platforms have the IBiSA label; some animal houses are recognised by AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) and the biobanks are AFNOR NF S96-900 compliant (DNA, blood, brain, tumour samples).
The support offered by NeurATRIS, with its GLP and non-GLP compliant facilities, will not only accelerate the development of your projects but also reduce the regulatory timeframe and associated risks as well as ensure their quality.
The facilities dedicated to the production of biotherapeutics are GMP compliant and each clinical protocol complies with ethical laws, particularly for patient cohorts. Similarly, NeurATRIS' clinical facilities comply with French and European legislation and regulations on good clinical practices.
Several NeurATRIS platforms have the IBiSA label; some animal houses are recognised by AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) and the biobanks are AFNOR NF S96-900 compliant (DNA, blood, brain, tumour samples).